Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 16/20 | 0.64 |
| ▸ | PIK3CA | P42336 | 13/20 | 0.59 |
| ▸ | PIK3CB | P42338 | 9/20 | 0.59 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.59 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.59 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.30 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.30 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13075390 | 0.89 | PIK3CD (0.69) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL659765 | 0.88 | PIK3CD (0.77) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL470241 | 0.86 | PIK3CD (0.79) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL13075389 | 0.86 | PIK3CD (0.79) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL13076084 | 0.85 | PIK3CD (0.66) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL19859026 | 0.85 | PIK3CD (0.81) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL19859021 | 0.85 | PIK3CD (0.78) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL16266147 | 0.84 | PIK3CD (0.64) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL461788 | 0.83 | PIK3CD (0.66) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 | |
| SCHEMBL463365 | 0.83 | PIK3CD (0.70) | PIK3CDPIK3CAPIK3CBPIK3CGPIK3R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100280029-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
| US-20100280045-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100280045-A1 | NOVEL COMPOUNDS | PLK3, PLK1, PLK2 | PIK3CD 73/4885PIK3CA 70/4885PIK3CB 51/4885 |
| US-20100280029-A1 | NOVEL COMPOUNDS | PIK3CD, PIK3CA, PIK3C2B | PIK3CD 1/4885PIK3CA 2/4885PIK3CB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.